Key Highlights

  • Cyclopharm's shares fell heavily in early Friday trade.
  • No new price-sensitive announcement dated to today was found to explain the size of the move, so this article does not claim a specific trigger.
  • The company faces execution, funding or timing risks as its plans progress.
  • Cyclopharm is a commercial-stage medical imaging company.

Cyclopharm (ASX:CYC) is facing a decisive stretch as rising US sales contrast with wider losses and delayed installation targets. The developments place attention on what the company has already delivered, what remains unproven and which milestones come next.

Approval Is Not the Same as Adoption

Cyclopharm's shares fell heavily in early Friday trade. No new price-sensitive announcement dated to today was found to explain the size of the move, so this article does not claim a specific trigger. What is verifiable, and relevant to why this stock has been volatile for months, is a pattern already visible in the company's own numbers: revenue keeps growing, but so do losses, and the pace of the company's most important growth driver - US adoption of its Technegas lung-imaging agent - has repeatedly been pushed back on timing, even as the underlying US regulatory position has not changed.

Cyclopharm is a commercial-stage medical imaging company. Its core product, Technegas, is a radioactive ventilation agent used mainly to diagnose pulmonary embolism and other lung conditions, and is sold in dozens of countries.

US Revenue Rises as Losses Widen

This is not a pre-revenue biotech: Technegas already holds US Food and Drug Administration approval, granted in 2023, for the diagnosis and management of pulmonary embolism. The current US story is about commercial rollout speed, not about awaiting a regulatory green light. Cyclopharm's Appendix 4D half-year report, lodged 24 August 2026 for the six months to 30 June 2026, showed revenue of $17.52 million, up 14% on the prior corresponding half, with Technegas revenue up 23% to $9.43 million and US Technegas revenue up 74% to $2.1 million off a small base.

Against that growth, the net loss after tax widened to $8.79 million from $7.69 million. Cash on hand was $12.2 million at 30 June 2026, after a $13.5 million placement and share purchase plan priced at $0.95 per share.

Clinical Guidance Resets the Clock

Revenue-generating US sites rose to 70 at 30 June 2026, and to 83 by 12 August 2026, from an engaged pipeline the company put at 1,684 sites. In July 2026 the company said short-term guidance for US installations, previously expected in the second half of calendar 2026, had been deferred because new international lung-imaging clinical guidelines from bodies including the SNMMI and EANM had not yet been published in the US Journal of Nuclear Medicine. Those guidelines were published on 29 July 2026, describing Technegas as 'generally preferred when available' - a clinical practice recognition, not a new regulatory approval.

Cyclopharm now expects 250-300 revenue-generating US sites after 31 December 2026, and has reaffirmed a medium-term target beyond 2,000 installations.

The Rollout Must Catch Up

Management told the market in August it believes the company has passed peak cash burn, an internal assessment rather than a guaranteed outcome. The half-year accounts also disclose a contingent liability: a $26 million damages claim from 4DMedical, which Cyclopharm's insurer has accepted and is now defending.

The Next Milestone

Cyclopharm now faces its next project and financial milestones. Their delivery will show whether the latest developments translate into sustained progress, while timing and funding remain important.